OrbiMed’s Puma Biotechnology PBYI Stock Holding History

OrbiMed’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-150,000	Closed	-$1.61M	–	141
2019 Q3	$1.61M	Buy	+150,000	New	+$1.62M	0.03%	109
2015 Q2	–	Sell	-50,000	Closed	-$11.8M	–	145
2015 Q1	$11.8M	Buy	+50,000	New	+$10.7M	0.1%	97
2014 Q4	–	Sell	-60,000	Closed	-$14.3M	–	136
2014 Q3	$14.3M	Sell	60,000 -25,000	-29%	-$5.13M	0.15%	86
2014 Q2	$5.61M	Buy	+85,000	New	+$6.04M	0.07%	108

Other funds holding PBYI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

OrbiMed's PBYI Position: Q4 2019 in Review

OrbiMed sold out of Puma Biotechnology (PBYI) in Q4 2019, closing a stake of 636,600 shares — an estimated $6.85M sold.

OrbiMed first reported a position in PBYI in Q2 2013 and held it in 23 quarters. The position peaked at $290M in Q3 2017. 133 funds tracked by Wall St. Rank hold PBYI as of Q4 2019.

OrbiMed reported no remaining Puma Biotechnology position as of Q4 2019 after selling out during the quarter.
OrbiMed sold 636,600 Puma Biotechnology shares in Q4 2019, an estimated $6.85M.
OrbiMed first reported a position in Puma Biotechnology in Q2 2013 and held it in 23 quarters.
OrbiMed's Puma Biotechnology position peaked at $290M in Q3 2017.
133 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2019.

Based on OrbiMed's 13F filing for Q4 2019, filed 14 Feb 2020.